Cancer Cachexia Conference
Molecular Mechanisms and Therapeutic Approaches

Boston, Massachusetts, USA
September 21-23, 2012
**Conference Title:** Cancer Cachexia: Molecular Mechanisms and Therapeutic Approaches  
Boston, September 21-23, 2012

**Meeting Program:**

**Friday, September 21, 2012**

1:00 pm  
Meeting Check In (Badge + Conference Books)  
Poster Setup

4:00-4:10 pm  
Introductory Remarks: Denis Guttridge

4:10-5:10 pm  
Keynote Address – David Glass (Novartis); “Mechanisms of Muscle Atrophy and Hypertrophy”  
Q/A -

5:15-8:00 pm  
Welcoming Reception

8:00 pm  
Poster Viewing

**Saturday, September 22, 2012**

7:30-8:30 am  
Continental Breakfast

**Session 1: Clinical Manifestations of Cancer Cachexia**  
(Chair: Aminah Jatoi)

8:30-9:00 am  
Speaker 1 – Ken Fearon (Edinburgh); “Classification of cancer cachexia”  
Q/A -

9:00-9:30 am  
Speaker 2 – Vickie Baracos (Alberta); “Body composition and prognostication in cancer”  
Q/A -

9:30-10:00 am  
Speaker 3 – Bruno Gagnon (Montreal); “Onset and progression of cancer cachexia, results from the Montreal longitudinal study”  
Q/A -

10:00-10:30 am  
Coffee Break

10:30-11:00 am  
Speaker 4 – Michael Sawyer (Alberta); “Interactions between antineoplastic therapy and cachexia: a medical oncology perspective”  
Q/A -

11:00-11:20 am  
Short Talk 1 – Nathan Stephens (Edinburgh); “Physical functions and sexual dimorphism”  
Q/A -

11:20-11:40 am  
Short Talk 2 – Chosen from Abstracts  
Q/A
11:40-12:00 pm  **Short Talk 3 – Chosen from Abstracts**  
Q/A

**12:00 pm**  
**Lunch**  
**Session 2, Part 1:**  
Basic Mechanisms of Muscle Wasting in Cancer Cachexia  
(Chair: Denis Guttridge)

**1:30-2:00 pm**  
**Speaker 1 – Alfred Goldberg (Boston); “New Insights into the Molecular Mechanisms of Muscle Atrophy”**  
Q/A-

**2:00-2:30 pm**  
**Speaker 2 – Josep Argiles (Barcelona); “Mechanisms of muscle wasting in cancer”**  
Q/A-

**2:30-3:00 pm**  
**Speaker 3 – Marco Sandri (Padova); “A Novel pathway in TGFbeta signaling that controls muscle cachexia”**  
Q/A-

**3:00-5:00 pm**  
**Poster Session (Judging) + Free Time**  
Session 3:  
Mechanisms of Muscle Wasting in Cancer Cachexia, Part II  
(Chair: Marion Couch)

**5:00-5:30 pm**  
**Speaker 4 – Denis Guttridge (Columbus); “Cellular signaling in cancer cachexia”**  
Q/A-

**5:30-6:00 pm**  
**Speaker 5 – Gerald Hoelfer (Austria); “The role of triglyceride lipases in cancer cachexia”**  
Q/A-

**6:00-6:20 pm**  
**Short Talk 1 – Teresa Zimmers (Philadelphia); “Stat3 in cancer cachexia”**  
Q/A -

**6:20-6:40 pm**  
**Short Talk 2 – Chosen from Abstracts**  
Q/A -

**6:40-7:00 pm**  
**Short Talk 3 – Chosen from Abstracts**  
Q/A

**7:00 pm**  
**Banquet Dinner**

**9:00 pm**  
**Evening Reception/Poster Viewing**

---

**Sunday, September 23, 2012**

**7:30-8:30 am**  
**Continental Breakfast**

Session 4:  
Involvement of Non-Muscle Tissue in Cancer Cachexia  
(Chair: Ken Fearon)
8:30-9:00 am  Speaker 1 – Jochen Springer (Berlin); “Cardiac muscle wasting and fibrosis in cancer”  Q/A  -

9:00-9:30 am  Speaker 2 – Tom Force (Philadelphia); “Chemotherapy-induced cardiotoxicity”  Q/A  -

9:30-10:00 am  Speaker 3 – Monte Willis (Chapel Hill); “Mechanisms of cardiac atrophy in cancer”  Q/A  -

10:00-10:30 am  Coffee Break

10:30-11:00 am  Speaker 4 – Dan Marks (Portland); “Neuroendocrine influences in cachexia”  Q/A  -

11:00-11:20 am  Short Talk 1 – Chosen from Abstracts  Q/A

11:20-11:40 am  Short Talk 2 – Chosen from Abstracts  Q/A

11:40-12:00 pm  Short Talk 3 – Chosen from Abstracts

12:00-1:30 pm  Lunch

Session 5
Therapeutic Targets and Clinical Trials in Cancer Cachexia
(Chair:  Vickie Baracos)

1:30-2:00 pm  Speaker 1 – HQ Han (Amgen); “Targeting myostatin as a potential therapy for cancer cachexia”  Q/A  -

2:00-2:20 pm  Short Talk – Egidio Del Fabbro (MD Anderson Cancer Center); “Targeting ghrelin system for the management of cachexia/anorexia syndrome”

2:20-2:50 pm  Speaker 2 – Florian Strasser (St. Gallen); “Choosing the right clinical endpoints for a cachexia trial”  Q/A  -

2:50-3:20 pm  Speaker Talk 3 - Speaker Talk 5 – Stefan Anker (Berlin); "Regulatory and statistical issues for treatment development in cancer cachexia: the SARM example.”  Q/A  -

3:20-3:40 pm  Coffee Break

3:40-4:10 pm  Speaker Talk 4 - Aminah Jatoi (Rochester); “The challenges of recruiting and retaining patients onto cancer cachexia trials  Q/A  -

4:10-4:40 pm  Speaker Talk 5 - Marion Couch (Burlington); “Integrating metabolomics into clinical trials”  Q/A  -
4:40-5:30 pm  Open Q/A w/Speakers
5:30-5:40 pm  Closing Remarks (Denis Guttridge)

Monday, September 24, 2012 – Departure